Tata 1mg has achieved a major profitability milestone, turning EBITDA positive across all its established businesses in FY26 as the digital healthcare platform continues scaling aggressively across pharmacy, diagnostics, specialty care, and AI-led preventive healthcare services. The development marks an important moment not only for Tata 1mg, but also for India’s rapidly evolving D2C ecosystem India, where integrated healthcare, omnichannel retail, and AI-powered personalisation are becoming key growth drivers.
In one of the most notable Indian D2C updates in the healthcare space, Tata 1mg said its diagnostics business crossed an annualised revenue run rate (ARR) of more than ₹600 crore during FY26 while maintaining double-digit EBITDA margins. The company’s diagnostics vertical also grew over 40% year-on-year, reflecting rising consumer adoption of preventive healthcare, at-home testing, and digital-first healthcare experiences across Direct-to-consumer India.
The company currently operates 19 NABL-accredited labs serving over 70 cities, with its National Reference Lab accredited by the College of American Pathologists (CAP). Tata 1mg said the diagnostics business is expected to remain a key pillar of future expansion as the company accelerates investments across radiology, specialised testing, and integrated healthcare services. The milestone adds to the growing momentum across D2C startup news and D2C business India, where healthcare-focused D2C brands India are increasingly blending technology, logistics, and omnichannel accessibility to scale sustainably.
Tata 1mg’s ePharmacy business, which the company claims is ranked number one in India, also achieved breakeven during FY26 while continuing to expand rapidly. The company said express medicine delivery within 30–60 minutes is now available across 10 cities as part of its larger omnichannel D2C strategy. Alongside online expansion, Tata 1mg has also scaled its offline retail presence to more than 280 stores across nine clusters and plans to increase that network to over 500 stores over the next 12 months.
The company’s Specialty Pharma business, spanning patient support programmes, adult vaccination, cancer care, obesity management, and chronic healthcare services, recorded approximately 65% growth during FY26. At the same time, its direct-to-consumer health products business crossed ₹200 crore ARR while remaining profitable, further strengthening Tata 1mg’s position within India’s fast-growing D2C wellness startups and healthcare ecosystem.
Tata 1mg also continues to invest aggressively in AI-powered healthcare infrastructure and predictive health technologies. Its AI-powered insights platform, Pulse, is now being actively used by more than 75 pharmaceutical companies, positioning the company as a growing health intelligence provider within India’s healthcare and pharma ecosystem. Consumer-facing offerings such as Health Insights Hub and Family Hub are aimed at building more personalised, preventive, and longitudinal healthcare experiences for users.
According to the company, FY26 represents a major inflection point after nearly a decade of building an integrated healthcare model that combines pharmacy, diagnostics, specialty care, offline retail, AI-led insights, and consumer health products under one platform. The company added that future growth across FY27 and beyond will focus on faster medicine delivery, diagnostics expansion, institutional partnerships, AI-first personalisation, and deeper omnichannel integration.
As D2C market trends 2025 continue shifting toward preventive healthcare, AI-driven experiences, and digitally integrated healthcare ecosystems, Tata 1mg’s profitability milestone highlights the growing maturity of India’s digital health commerce space. With strong operational momentum, expanding infrastructure, and increasing consumer trust, Tata 1mg is rapidly strengthening its position as one of India’s most scaled and trusted omnichannel healthcare platforms within the broader D2C industry news landscape.
